Work

Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials

Year: 2026

Type: preprint

Source: Research Square

DOI: 10.21203/rs.3.rs-11082091/v1

Authors: Maria Dermit, Helen M. Colhoun, Ludger J. E. Goeminne, Donna Ryan, Kasper Adelborg, Dylan Belmont-Rausch, Kristoffer Jensen Kolnes, Filip K. Knop, Sarah Amandine Caroline Voisin, Vadim N. Gladyshev, Lotte Bjerre Knudsen, Alejandro Aguayo Orozco

Institutions: Institute of Genetics and Cancer, University of Edinburgh, Brigham and Women's Hospital, Harvard University, Pennington Biomedical Research Center, Novo Nordisk (Denmark)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Novo Nordisk

OpenAlex ID: W7214008066

Cites: 31

Cited by:

Related to: 10